Results Month, page-5

Greetings from a new poster and thanks to all the very high quality contributors who I have been learning from for past 3 months.

I'm in ACL in a big way and quietly confident. Having said that, I'm a refugee from SPL, which outfit suffers from the same inability as ACL to communicate with its retail owners. And the management of which seems unable to get a product to market or sign a financial deal even though they own very good IP. Anyway, I hope for better from ACL. Us biotech investors are by definition, optimists.

But, being experienced at the weaseling words of SPL and ACL and others I offer for the opinion of fellow posters the subtle change in time line snuck in by ACL in the Prelim Final Report of 29/8. In common with you all I always thought the results of phase 3 would be by end of September, but take a closer look at the second line of the following extract. Does anyone else think that "end of September quarter 2014" allows any date up to New Years Eve?

"HyACT: Alchemia has previously announced that we expect to release top line data results from the Phase III trial by end of September quarter 2014. We are currently working towards finalising the database, and we will notify the market should there be any change to the expected timing of results becoming available. This represents an important milestone and marks a pivotal point in the development of HA-Irinotecan. Positive data from this trial will pave the way for commercialisation of the drug in the US and Europe and validate the HyACT platform, which can be used to optimize the clinical effectiveness of other cancer drugs. In addition, the investigator-sponsored Phase II CHIME trial testing HA-Irinotecan combined with Merck Serono’s Erbitux® recruited its first patient. Enrolment is progressing well with 5 patients enrolled to date. HA-Irinotecan’s second investigator sponsored Phase II trial in small cell lung cancer (SCLC) has also made solid progress with 32 patients treated to date."